Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations: A Single-arm, Phase II Multi-center Trial

NCT05277701 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT05277701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05277701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations: A Single-arm, Phase II Multi-center Trial
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2022
Completion date
December 31, 2024
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc